Titan Minerals Ltd (ASX:TTM) Announces Substantial Resource Drilling Results
Titan Minerals (ASX:TTM) reports significant Au and Ag intercepts from resource drilling at the Dynasty Gold Project, advancing towards a mid-2025 resource update.
Tag: Investor Relations
Prime Financial Group Limited (ASX:PFG) Achieves Altor Capital EBITDA Target
Prime Financial Group (ASX:PFG) achieves EBITDA target for Altor Capital acquisition within the first year, enhancing its capabilities and plans for further acquisitions.
Elixir Energy Limited (ASX:EXR) Announces Trading Halt
Elixir Energy Limited (ASX:EXR) halts trading pending announcement of Taroom Trough position expansion.
Prospech Limited (ASX:PRS) Announces Strong Drill Assay Results
Prospech Limited (ASX:PRS) reports new drill assay results at the Korsnäs REE project, expanding resource estimates and highlighting significant rare earth elements.
ikeGPS Group Limited (ASX:IKE) Rejects Acquisition Offer
ikeGPS Group Limited (ASX:IKE) rejects a 62% premium acquisition offer, continuing to focus on growth strategy and strong operational performance.
Atlas Arteria (ASX:ALX) Announces New French Temporary Supplemental Tax
Atlas Arteria (ASX:ALX) outlines the impact of France’s new temporary supplemental tax on its financial obligations.
Charter Hall Long WALE REIT (ASX:CLW) Announces 2025 Half Year Results
Charter Hall Long WALE REIT (ASX:CLW) reports strong financial performance and strategic portfolio updates in its 2025 half year results.
Charter Hall Long WALE REIT (ASX:CLW) Publishes 2025 Half Year Results
Charter Hall Long WALE REIT (ASX:CLW) announces its 2025 half-year results, highlighting stable financial performance and strategic portfolio developments.
ReNu Energy Limited (ASX:RNE) Announces Sale of Countrywide Hydrogen Business
ReNu Energy Limited (ASX:RNE) is set to sell its Countrywide Hydrogen Business, including a Tasmanian green hydrogen project, pending shareholder approval.
Actinogen Medical (ASX:ACW) Publishes Clinical Pharmacology Study on Xanamem
Actinogen Medical (ASX:ACW) publishes study validating the 10 mg dose of Xanamem for CNS disease treatment, supporting ongoing clinical trials.